Valeant Pharmaceuticals Price Target Increased to $130.00 by Analysts at CRT Capital (VRX)
Analysts at CRT Capital raised their price target on shares of Valeant Pharmaceuticals (NYSE:VRX) from $110.00 to $130.00 in a research report issued to clients and investors on Monday, American Banking and Market News reports. The firm currently has a “buy” rating on the stock. CRT Capital’s price target would indicate a potential upside of 17.11% from the company’s current price.
Valeant Pharmaceuticals (NYSE:VRX) opened at 111.01 on Monday. Valeant Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $113.79. The stock has a 50-day moving average of $102.1 and a 200-day moving average of $87.91. The company’s market cap is $37.025 billion.
Valeant Pharmaceuticals (NYSE:VRX) last announced its earnings results on Wednesday, August 7th. The company reported $1.34 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.28 by $0.06. The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $820.09 million. During the same quarter last year, the company posted $1.01 earnings per share. Valeant Pharmaceuticals’s revenue was up 33.6% compared to the same quarter last year.
Several other analysts have also recently commented on the stock. Analysts at BMO Capital Markets set a $123.00 price target on shares of Valeant Pharmaceuticals in a research note to investors on Wednesday, October 2nd. Separately, analysts at Guggenheim initiated coverage on shares of Valeant Pharmaceuticals in a research note to investors on Thursday, September 26th. They set a “buy” rating on the stock. Finally, analysts at Goldman Sachs Group Inc. initiated coverage on shares of Valeant Pharmaceuticals in a research note to investors on Tuesday, September 17th. They set a “conviction-buy” rating and a $130.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. Valeant Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $111.05.
Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.